Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

Stock Information for Applied DNA Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Applied DNA Sciences Inc.

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.